A recently published study found that the auto-injector device used to deliver a biosimilar etanercept was preferable to the auto-injector device used to deliver reference etanercept (Enbrel) among patients with rheumatoid arthritis and healthcare providers who treat patients with RA.
A recently published study found that the auto-injector device used to deliver a biosimilar etanercept was preferable to the auto-injector device used to deliver reference etanercept (Enbrel) among patients with rheumatoid arthritis (RA) and healthcare providers who treat patients with RA.
The study, funded by Merck, sponsor of the biosimilar etanercept product (Brenzys, which is also marketed as Benepali) compared the biosimilar’s auto-injector—which has no push button requiring use of the patient’s thumb, which allows 1-handed delivery, and which allows for visual and auditory confirmation of dose delivery—with the auto-injector of the reference etanercept. The study, conducted in Canada and Australia, was a counterbalanced crossover trial in which patients with RA (n = 191) and healthcare professionals (HCPs), comprising nurses and rheumatologists (n = 90), injected both devices into pads representing skin and reported on the ease of use.
All participants were blinded to the study sponsor. The researchers presented each participant with both devices in a counterbalanced order among participants. After receiving a demonstration, participants used both devices, then completed a forced-choice questionnaire.
The survey results for patients, of whom 157 (82.2%) were naïve to auto-injector experience for RA, were as follows:
Results for the HCPs were as follows:
The study’s authors note that their trial was limited by the fact that patients injected into a pad rather than into themselves, and also that participants used each auto-injector once rather than over the course of many doses of therapy, as preference patterns could vary with repeated use.
The researchers concluded that patients with RA and HCPs with experience in treating patients with RA indicated an overall preference for the biosimilar etanercept’s auto-injector device, and that the preference extended to various aspects of use. The researchers say that these findings can be used to understand the real-world experiences of patients who use such devices, and that healthcare stakeholders can use these results to make informed decisions when selecting an etanercept product for the management of RA.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.